AngioDynamics (ANGO) Stock Rating Lowered by BidaskClub

Share on StockTwits

AngioDynamics (NASDAQ:ANGO) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, September 20th.

Several other equities research analysts also recently commented on the stock. Canaccord Genuity reissued a “hold” rating and set a $20.00 target price on shares of AngioDynamics in a research report on Thursday, July 12th. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Finally, Raymond James downgraded shares of AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $18.44.

ANGO stock traded up $0.09 during midday trading on Thursday, hitting $20.15. The stock had a trading volume of 194,162 shares, compared to its average volume of 246,983. The firm has a market cap of $806.02 million, a price-to-earnings ratio of 27.23 and a beta of 0.86. The company has a quick ratio of 1.55, a current ratio of 2.64 and a debt-to-equity ratio of 0.16. AngioDynamics has a 1-year low of $15.16 and a 1-year high of $24.49.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The company had revenue of $85.34 million for the quarter, compared to analyst estimates of $84.05 million. During the same quarter in the prior year, the company posted $0.13 EPS. AngioDynamics’s revenue for the quarter was down .1% on a year-over-year basis. Research analysts expect that AngioDynamics will post 0.85 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of ANGO. JPMorgan Chase & Co. grew its position in AngioDynamics by 958.2% in the 1st quarter. JPMorgan Chase & Co. now owns 895,414 shares of the medical instruments supplier’s stock worth $15,447,000 after purchasing an additional 810,794 shares in the last quarter. Tributary Capital Management LLC bought a new position in shares of AngioDynamics during the 2nd quarter valued at approximately $9,681,000. Segall Bryant & Hamill LLC grew its position in shares of AngioDynamics by 141.1% during the 1st quarter. Segall Bryant & Hamill LLC now owns 651,782 shares of the medical instruments supplier’s stock valued at $11,243,000 after acquiring an additional 381,497 shares during the period. BlackRock Inc. grew its position in shares of AngioDynamics by 7.3% during the 2nd quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock valued at $121,848,000 after acquiring an additional 374,834 shares during the period. Finally, Heartland Advisors Inc. bought a new position in shares of AngioDynamics during the 1st quarter valued at approximately $5,990,000. 98.17% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Story: Marijuana Stocks Future Looks Bright

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.